Source:http://linkedlifedata.com/resource/pubmed/id/19843681
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2009-11-10
|
pubmed:abstractText |
The Women's Health Initiative randomized trials showed a reduction in colorectal cancer risk with the use of estrogen plus progesterone (E + P), but not with estrogen alone (E-only), after intervention periods <7 years. Using data from the Cancer Prevention Study II Nutrition Cohort, we examined associations of colorectal cancer risk with E-only and E + P, including analyses by recency and duration of hormone use. During 13.2 years of follow-up, 776 cases of invasive colorectal cancer occurred among 67,412 postmenopausal women participants. Cox proportional hazards models were used to estimate multivariate-adjusted relative risks (RR) and 95% confidence intervals (95% CI) of colorectal cancer for current and former hormone users according to hormone type and duration of use. Relative to women who never used postmenopausal hormones, current, but not former, use of E-only was associated with a reduced risk of colorectal cancer (RR 0.76; 95% CI, 0.59-0.97). Among current E-only users, duration of use was inversely and linearly associated with risk (P(trend) = 0.01). Use of E-only for <5 years was not associated with reduced risk, whereas use for >or=20 years was associated with a 45% reduction in risk (RR, 0.55; 95% CI, 0.36-0.86). There were no statistically significant associations between E + P and colorectal cancer risk. Our results suggest a strong inverse association of long-term use of E-only with colorectal cancer risk, underscoring the importance of collecting data on duration of hormone use in epidemiologic studies of postmenopausal hormones and risk of disease.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1538-7755
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2835-41
|
pubmed:meshHeading |
pubmed-meshheading:19843681-Aged,
pubmed-meshheading:19843681-Cohort Studies,
pubmed-meshheading:19843681-Colorectal Neoplasms,
pubmed-meshheading:19843681-Estrogen Replacement Therapy,
pubmed-meshheading:19843681-Female,
pubmed-meshheading:19843681-Humans,
pubmed-meshheading:19843681-Incidence,
pubmed-meshheading:19843681-Middle Aged,
pubmed-meshheading:19843681-Postmenopause,
pubmed-meshheading:19843681-Progesterone,
pubmed-meshheading:19843681-Progestins,
pubmed-meshheading:19843681-Prognosis,
pubmed-meshheading:19843681-Prospective Studies,
pubmed-meshheading:19843681-Risk Factors,
pubmed-meshheading:19843681-Time Factors,
pubmed-meshheading:19843681-Women's Health
|
pubmed:year |
2009
|
pubmed:articleTitle |
Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II.
|
pubmed:affiliation |
Department of Epidemiology, American Cancer Society, Atlanta, Georgia 30303, USA. janet.hildebrand@cancer.org
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|